–Midwest CEPAC to vote on the overall value of treatments during November 29 public meeting– BOSTON, November 13, 2018 – The Institute for Clinical and Economic Review (ICER) today released an Evidence Report assessing the comparative clinical effectiveness and value of biologic treatments for asthma associated with type 2 inflammation and/or allergic asthma. The report focuses on […]
Read More
11/13/2018
– Report will be subject of November Midwest CEPAC meeting; Open input now being accepted until May 10th – BOSTON, April 24, 2018 – The Institute for Clinical and Economic Review (ICER) today announced plans to develop a review assessing the comparative clinical effectiveness and value of biologic therapies for moderate-to-severe asthma. The report is […]
Read More
04/24/2018
Boston, Mass. And San Francisco, Calif., March 14, 2016 – The Institute for Clinical and Economic Review (ICER) has released two final reports titled Mepolizumab (Nucala®, GlaxoSmithKline plc.) for the Treatment of Severe Asthma with Eosinophilia: Effectiveness, Value, and Value-Based Price Benchmarks and Insulin Degludec (Tresiba®, Novo Nordisk A/S) for the Treatment of Diabetes: Effectiveness, Value, and Value-Based Price Benchmarks. […]
Read More
03/14/2016
Prices for TKIs Well Aligned With Added Benefits for Patients; Prices for PD-1s Too High Boston, Mass., November 1, 2016– The Institute for Clinical and Economic Review (ICER) has released a Final Evidence Report and Meeting Summary on the comparative clinical effectiveness and value of PD-1 immunotherapies and tyrosine kinase inhibitors (TKIs) for treatment of advanced non-small […]
Read More
11/01/2016
Public Comments
Closed